Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) Director Daniel Gold sold 602,021 shares of the stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $38.24, for a total value of $23,021,283.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Daniel Allen Gold also recently made the following trade(s):
- On Monday, November 16th, Daniel Gold sold 779,741 shares of Roivant Sciences stock. The stock was sold at an average price of $39.14, for a total value of $30,519,062.74.
Roivant Sciences Price Performance
Roivant Sciences stock opened at $38.73 on Thursday. The firm has a market capitalization of $28.06 billion, a P/E ratio of -61.48 and a beta of 1.23. Roivant Sciences Ltd. has a one year low of $19.96 and a one year high of $42.50. The business has a fifty day moving average price of $37.26 and a 200-day moving average price of $32.50.
Hedge Funds Weigh In On Roivant Sciences
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. increased its stake in Roivant Sciences by 18.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock worth $295,965,000 after acquiring an additional 1,286,464 shares during the last quarter. Perceptive Advisors LLC raised its holdings in shares of Roivant Sciences by 3.8% in the 1st quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company’s stock valued at $229,507,000 after acquiring an additional 300,000 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in shares of Roivant Sciences by 20.3% during the 3rd quarter. Pictet Asset Management Holding SA now owns 4,173,123 shares of the company’s stock valued at $152,597,000 after acquiring an additional 704,783 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Roivant Sciences by 8.0% during the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock valued at $87,638,000 after acquiring an additional 235,493 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Roivant Sciences by 6.1% during the first quarter. Janus Henderson Group PLC now owns 3,095,448 shares of the company’s stock worth $85,790,000 after purchasing an additional 177,339 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on the company. HC Wainwright increased their price objective on Roivant Sciences from $47.00 to $48.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 24th. Citigroup raised their price objective on shares of Roivant Sciences from $46.00 to $56.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Guggenheim boosted their price objective on shares of Roivant Sciences from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Monday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.82.
View Our Latest Analysis on Roivant Sciences
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.
Recommended Stories
- Five stocks we like better than Roivant Sciences
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
